Deinove 2018 Annual Results: a year of significant progress - Nasdaq

Deinove 2018 Annual Results: a year of significant progress  Nasdaq

Finalization of the acquisition of DNV3837, a promising antibiotic for treating severe gastrointestinal infections caused by Clostridium difficile,.



Comments

Popular posts from this blog

CDC says skin-disfiguring parasite may be endemic in Texas, present in other states - NBC News